HLS Therapeutics Inc. (TSX:HLS)

Market Cap	142.30M +1.3%
Revenue (ttm)	76.10M -2.0%
Net Income	-17.04M
EPS	-0.54
Shares Out	31.27M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,221
Average Volume	6,120
Open	4.400
Previous Close	4.400
Day's Range	4.330 - 4.610
52-Week Range	3.930 - 5.765
Beta	0.81
RSI	69.98
Earnings Date	May 14, 2026

About HLS Therapeutics

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances and simplifies the mandatory safety blood monitoring process for patients that are prescribed Clozaril; Nilemdo, a bempedoic acid product for cardiovas...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Craig Millian
• Employees: 85
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: HLS

Financial Performance

In 2025, HLS Therapeutics's revenue was $55.50 million, a decrease of -1.98% compared to the previous year's $56.62 million. Losses were -$12.43 million, -36.76% less than in 2024.

Financial numbers in USD